Vanguard Group’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Vanguard Group’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-227,804	Closed	-$149K	–	4319
2024 Q4	$149K	Hold	227,804	–	–	﹤0.01%	4134
2024 Q3	$86.1K	Buy	227,804 +174,000	+323%	+$154K	﹤0.01%	4208
2024 Q2	$68.3K	Hold	53,804	–	–	﹤0.01%	4264
2024 Q1	$102K	Buy	+53,804	New	+$103K	﹤0.01%	4241

Other funds holding NKGN

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

UOC

University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Vanguard Group's NKGN Position: Q1 2025 in Review

Vanguard Group sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2025, closing a stake of 227,804 shares — an estimated $149K sold.

Vanguard Group first reported a position in NKGN in Q1 2024 and held it in 4 quarters. The position peaked at $149K in Q4 2024. 3 funds tracked by Wall St. Rank hold NKGN as of Q1 2025.

Vanguard Group reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Vanguard Group sold 227,804 NKGen Biotech, Inc. Common Stock shares in Q1 2025, an estimated $149K.
Vanguard Group first reported a position in NKGen Biotech, Inc. Common Stock in Q1 2024 and held it in 4 quarters.
Vanguard Group's NKGen Biotech, Inc. Common Stock position peaked at $149K in Q4 2024.
3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2025.

Based on Vanguard Group's 13F filing for Q1 2025, filed 9 May 2025.